MYL3 Polyclonal antibody

MYL3 Polyclonal Antibody for IHC, IP, WB,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IP, IHC,ELISA

Conjugate

Unconjugated

Cat no : 10913-1-AP

Synonyms

Cardiac myosin light chain 1, CMH8, CMLC1, MLC1SB, MLC1V, MYL3, Myosin light chain 3, VLC1



Tested Applications

Positive WB detected inmouse heart tissue, human heart tissue, mouse skeletal muscle tissue
Positive IP detected inmouse heart tissue
Positive IHC detected inhuman heart tissue, human lung cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:2000-1:14000 for WB
Immunohistochemistry (IHC)IHC : 1:500-1:2000
Sample-dependent, check data in validation data gallery

Published Applications

WBSee 1 publications below

Product Information

10913-1-AP targets MYL3 in WB, IP, IHC,ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen MYL3 fusion protein Ag1364
Full Name myosin, light chain 3, alkali; ventricular, skeletal, slow
Calculated molecular weight 22 kDa
Observed molecular weight 22-27 kDa
GenBank accession numberBC009790
Gene symbol MYL3
Gene ID (NCBI) 4634
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

MYL3, also named as MLC1v, is an essential light chain of myosin that is associated with muscle contraction. It is expressed in ventricular and slow skeletal muscle. MYL3 may serve as a target for caspase-3 in dying cardiomyocytes. Mutations of MYL3 gene cause hypertrophic cardiomyopathy. MYL3 has been identified as potential serum biomarker for drug induced myotoxicity. Great increase in MYL3 serum concentration has been observed in rats with cardiac and skeletal muscle injury. (PMID:21685905)

Protocols

Product Specific Protocols
WB protocol for MYL3 antibody 10913-1-APDownload protocol
IHC protocol for MYL3 antibody 10913-1-APDownload protocol
IP protocol for MYL3 antibody 10913-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Nat Biotechnol

A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.

Authors - Addona Terri A TA